Enlivex (ENLV) Asset Utilization Ratio (2024 - 2025)
Enlivex (ENLV) posted quarterly Asset Utilization Ratio of 0.95 for Q1 2025, up 2325.45% year-over-year from 0.04 in Q1 2024, and up 31.84% quarter-over-quarter from 0.72 in Q4 2024.
Enlivex (ENLV) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
Enlivex's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.95 for Q1 2025.
- In Q1 2025, Asset Utilization Ratio rose 2325.45% year-over-year to 0.95; the TTM figure through Mar 2025 stood at 0.95 (up 2325.45% YoY), while the FY2024 annual figure was 1.15, down 102.85% from the prior year.
- Asset Utilization Ratio for Q1 2025 stood at 0.95, up from 0.72 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.95 in Q1 2025, with the low at 0.04 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.90 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.54 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.13 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.13 |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 0.95 |
| Dec 31, 2024 | 0.72 |
| Mar 31, 2024 | 0.04 |